NV-MOVELLA
16.7.2024 16:01:31 CEST | Business Wire | Press release
Movella, a leading provider of full-stack solutions for digitizing movement, today announced it has enhanced its Xsens MTi™ inertial sensor modules for autonomous machines and edge AI applications. The Xsens MTi sensors can be easily integrated with the NVIDIA Jetson™ platform for edge AI and robotics, offering full compatibility with the NVIDIA Jetson AGX Orin™, NVIDIA Jetson Orin™ NX, and NVIDIA Jetson Orin Nano™ system-on-modules.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716567003/en/
(Graphic: Business Wire)
The highly compact Xsens MTi sensors, also called “IMU”, are renowned for their high accuracy, reliability, and low latency, even under adverse conditions. They provide industrial-grade, real-time measurements of motion, orientation, and global position (GNSS), which are critical for navigating and controlling a wide range of mobile robots and smart automation applications, whether aerial, land-based, or subsea. Offering compatibility with the powerful AI capabilities of the NVIDIA Jetson platform, the Xsens MTi inertial sensors will help customers bring their intelligent and autonomous systems faster to the market.
The easy integration of NVIDIA Jetson Orin modules with Xsens MTi sensors will help enable more intelligent and efficient autonomous systems. Movella is a member of the NVIDIA Partner Network (NPN).
“The mobile robot market is undergoing massive growth and transformation as autonomous platforms such as autonomous mobile robots (AMRs) get widely adopted indoors and outdoors. Collaborating with NVIDIA on the Jetson platform integration has helped us advance the use of Xsens MTi sensors in mobile robotics and edge AI,” said Meindert Zeeuw, Director of the “Automation & Mobility” Line of Business at Movella. “The seamless integration of Xsens MTi’s precise and real-time data with NVIDIA Jetson’s accelerated computing capabilities will help innovators further in developing systems that can navigate, perceive, and interact with their environments with even more accuracy and agility.”
This integration highlights the momentum of the industrial inertial sensor market, particularly in logistics (autonomous robots, autonomous vehicles) and sea-based (ROV/AUV) applications. This segment has a projected 16% CAGR expected from 2021 to 2027, reaching an estimated value of USD 1.1 billion. Movella’s work underscores the industry’s rapid innovation and adoption of industrial inertial sensors, positioning the company to drive transformative advancements in intelligent automation within industrial applications.
About Movella
Movella is a leading full-stack provider of sensors, software, and analytics that enable the digitization of movement. Movella serves the automation & mobility, entertainment and health & sports markets. Movella's innovations enable customers to capitalize on the value of movement by transforming data into meaningful and actionable insights. Partnering with leading global brands such as ABB Marine, Hewlett Packard, Kongsberg, Clearpath Robotics, Toyota, Siemens, Electronic Arts, EPIC Games, 20th Century Studios, Netflix and more than 500 sports organizations, Movella is creating extraordinary outcomes that move humanity forward. To learn more, please visit www.movella.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716567003/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom